Bronchial thermoplasty for severe asthma: A position statement of the Indian chest society

Madan, Karan; Mittal, Saurabh; Suri, Tejas M; Jain, Avinash; Mohan, Anant; Hadda, Vijay; Tiwari, Punit; Guleria, Randeep; Talwar, Deepak; Chaudhri, Sudhir; Singh, Virendra; Swarnakar, Rajesh; Bharti, Shreekant; Garg, Rakesh; Gupta, Nishkarsh; Kumar, Vikas; Agarwal, Ritesh; Aggarwal, Ashutosh N.; Ayub, Irfan Ismail; Chhajed, Prashant N.; Dhamija, Amit; Dhar, Raja; Dhooria, Sahajal; Gonuguntla, Hari Kishan; Goyal, Rajiv; Koul, Parvaiz A; Kumar, Rajiv; Maturu, Venkata Nagarjuna; Mehta, Ravindra; Parakh, Ujjwal; Pattabhiraman, V R; Narasimhan, Raghupathi; Sehgal, Inderpaul Singh; Srinivasan, Arjun; Venkatnarayan, Kavitha

doi:10.4103/lungindia.lungindia_418_19

Cited by 2 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These must be addressed appropriately before considering a patient for BT. [ 2 ] All the patients reported in this multicenter study fulfilled the criteria of severe asthma despite correction of modifiable factors.…”

Section: Discussionmentioning

confidence: 99%

“…Age higher than 65 years and a percent predicted FEV1 < 60 are considered as conditional inclusion criteria for BT. [ 2 ] A lower FEV1 may be associated with a greater risk of complications during and following the procedure, while safety data on older patients are sparse. [ 2 4 15 16 ] A history of asthma exacerbation requiring mechanical ventilation was present in 14% of patients.…”

Section: Discussionmentioning

confidence: 99%

“…[ 2 ] A lower FEV1 may be associated with a greater risk of complications during and following the procedure, while safety data on older patients are sparse. [ 2 4 15 16 ] A history of asthma exacerbation requiring mechanical ventilation was present in 14% of patients. Indeed, a history of asthma exacerbation requiring mechanical ventilation is also considered a relative contraindication for BT.…”

Section: Discussionmentioning

confidence: 99%

“…Although the exact prevalence data in India are lacking, an estimated 1–2 million adults in India have severe asthma. [ 2 ]…”

Section: Introductionmentioning

confidence: 99%

“…Guidelines on the technical performance and patient selection for BT in India were recently published. [ 2 ] However, there is no published experience on the utility and safety of BT in severe asthma from India. We collated the experience with the initial cases undergoing BT at four centers across India.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A multicenter study on the safety and efficacy of bronchial thermoplasty in adults with severe asthma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and Aim: Bronchial thermoplasty (BT) is a treatment option for patients with severe asthma. BT involves controlled delivery of radiofrequency energy using a bronchoscopic catheter, thereby reducing bronchial hyperreactivity. Herein, we describe our experience on the safety and efficacy of BT in severe asthma. Methods: This was a retrospective multicenter study of subjects who underwent BT at four centers across India. Results: We included 36 subjects (mean ± standard deviation [SD] age, 50.9 ± 11.5 years, women [69.44%]) undergoing 105 BT treatment sessions. All the subjects met the American Thoracic Society/European Respiratory Society criteria for severe asthma, 22.2% were requiring oral maintenance glucocorticoids. The mean ± SD baseline %predicted forced expiratory volume in one second (FEV1) was 62.07 ± 18.54. The median interquartile range (IQR) annual asthma exacerbation rate in the year preceding BT was 3.5 (1–10). We encountered intraprocedural complications in 7 (6.7%) sessions. An exacerbation of asthma following BT occurred in 6 (5.7%) procedures. We observed a significant improvement in the asthma control test and the asthma control questionnaire scores following BT. The quality of life (asthma quality of life questionnaire) also significantly improved. We noted a significant reduction in the number of exacerbations following BT (median [IQR], 3 [1–10] per year pre-BT versus 0.5 [0–3] per year post-BT, P < 0.001). No significant change occurred in the %predicted FEV1 following BT. Conclusion: BT is a feasible treatment option in patients with severe asthma. More extensive studies are required to establish the efficacy of BT in real-life settings.

show abstract

Section: Discussionmentioning

confidence: 99%